FDA Approves Xolair® (omalizumab) for Subcutaneous Use for People with Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives

March 21st, 2014

On March 21, 2014, the FDA approved Xolair for the treatment of chronic idiopathic urticaria (CIU), a form of chronic hives for people 12 years of age and older who remain symptomatic despite treatment with H1-antihistamine therapy.

Sandra Horning, M.D.

“Chronic idiopathic urticaria can be difficult to manage because its causes are unknown, and other approved medicines aren’t effective enough for many patients. We are pleased to have Xolair as a new option for people with this serious skin condition.”